Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

B. Atkins, Michael; J. Lee, Sandra; Chmielowski, Bartosz; A. Tarhini, Ahmad; I. Cohen, Gary; Truong, Thach‐Giao; Moon, Helen; Davar, Diwakar; Allen O’Rourke, Mark; J. Stephenson, Joseph; D. Curti, Brendan; J. Urba, Walter; M. Brell, Joanna; Funchain, Pauline; Kendra, Kari; P. Ikeguchi, Alexandra; J. Jaslowski, Anthony; Bane, Charles; Taylor, Mark; Bajaj, Madhuri; M. Conry, Robert; J. Ellis, Robert; F. Logan, Theodore; Laudi, Noel; A. Sosman, Jeffrey; G. Crockett, David; L. Pecora, Andrew; J. Okazaki, Ian; Reganti, Sowjanya; Chandra, Sunandana; Guild, Samantha; X. Chen, Helen; Streicher, Howard; D. Wolchok, Jedd; Ribas, Antoni; M. Kirkwood, John

doi:10.1200/jco.22.01763

Public

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Published in Journal of Clinical Oncology • Sep 27, 2022

Authors:

Michael B. Atkins

Sandra J. Lee

Bartosz Chmielowski

Abstract

PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the ...

Subject

Trametinib

Medicine

Ipilimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!